Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:ERAS NASDAQ:JANX NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$10.33+0.9%$10.67$3.85▼$12.43$1.56B1.921.54 million shs1.71 million shsERASErasca$1.39-1.8%$1.46$1.01▼$3.31$400.85M1.05812,222 shs804,375 shsJANXJanux Therapeutics$23.56-1.9%$24.74$22.48▼$71.71$1.42B2.86800,036 shs601,583 shsSDGRSchrodinger$19.53-3.9%$21.75$16.60▼$28.47$1.49B1.67942,510 shs1.12 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies+0.88%-3.91%-10.02%+4.98%+127.03%ERASErasca-1.77%-20.11%-4.14%-12.03%-55.87%JANXJanux Therapeutics-1.87%-9.24%-2.08%-28.35%-41.97%SDGRSchrodinger-3.94%-12.15%-6.82%-22.78%-12.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies3.0058 of 5 stars1.42.00.04.22.82.50.6ERASErasca2.0736 of 5 stars3.50.00.00.01.22.51.3JANXJanux Therapeutics2.4087 of 5 stars3.52.00.00.03.61.70.0SDGRSchrodinger2.5777 of 5 stars3.42.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.83Moderate Buy$11.339.71% UpsideERASErasca 3.00Buy$4.57228.88% UpsideJANXJanux Therapeutics 3.08Buy$91.89290.02% UpsideSDGRSchrodinger 2.75Moderate Buy$32.7567.69% UpsideCurrent Analyst Ratings BreakdownLatest ERAS, ADPT, SDGR, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $30.007/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.007/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.006/18/2025ADPTAdaptive BiotechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.005/5/2025ADPTAdaptive BiotechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.005/2/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M8.77N/AN/A$1.37 per share7.54ERASErascaN/AN/AN/AN/A$1.50 per shareN/AJANXJanux Therapeutics$9.34M149.33N/AN/A$19.49 per share1.21SDGRSchrodinger$207.54M6.91N/AN/A$5.78 per share3.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%8/5/2025 (Estimated)ERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%8/6/2025 (Estimated)Latest ERAS, ADPT, SDGR, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ERASErasca-$0.12N/AN/AN/AN/AN/A8/6/2025Q2 2025JANXJanux Therapeutics-$0.50N/AN/AN/A$0.30 millionN/A8/6/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24N/AN/AN/A$49.40 millionN/A5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.922.82ERASErascaN/A12.3512.35JANXJanux TherapeuticsN/A58.4758.47SDGRSchrodingerN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%ERASErasca67.78%JANXJanux Therapeutics75.39%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%ERASErasca14.40%JANXJanux Therapeutics8.10%SDGRSchrodinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million142.19 millionOptionableERASErasca120283.29 million242.49 millionOptionableJANXJanux Therapeutics3059.18 million54.38 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableERAS, ADPT, SDGR, and JANX HeadlinesRecent News About These CompaniesCritical Survey: Schrodinger (NASDAQ:SDGR) versus Bullfrog AI (NASDAQ:BFRG)August 1 at 3:49 AM | americanbankingnews.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $4.03 Million in Schrodinger, Inc. (NASDAQ:SDGR)July 29, 2025 | marketbeat.comARK Investment Management LLC Has $45.29 Million Stake in Schrodinger, Inc. (NASDAQ:SDGR)July 27, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Shares Sold by Nikko Asset Management Americas Inc.July 27, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Holdings Lowered by Baillie Gifford & Co.July 27, 2025 | marketbeat.comCloudAlpha Capital Management Limited Hong Kong Acquires New Shares in Schrodinger, Inc. (NASDAQ:SDGR)July 26, 2025 | marketbeat.comSchrödinger to Announce Second Quarter 2025 Financial Results on August 6July 26, 2025 | finance.yahoo.comEnvestnet Asset Management Inc. Grows Position in Schrodinger, Inc. (NASDAQ:SDGR)July 26, 2025 | marketbeat.comSchrödinger to Announce Second Quarter 2025 Financial Results on August 6July 25, 2025 | businesswire.comSchrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJuly 23, 2025 | zacks.comSchrodinger (SDGR) Projected to Post Earnings on WednesdayJuly 23, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Stock Price Up 8.6% - Here's WhyJuly 21, 2025 | marketbeat.comMaterial Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and CollaborationJuly 18, 2025 | globenewswire.comMassachusetts Financial Services Co. MA Sells 186,228 Shares of Schrodinger, Inc. (NASDAQ:SDGR)July 18, 2025 | marketbeat.comAjax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK TargetJuly 17, 2025 | finance.yahoo.comKeyCorp Has Lowered Expectations for Schrodinger (NASDAQ:SDGR) Stock PriceJuly 14, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Position Raised by Stephens Investment Management Group LLCJuly 13, 2025 | marketbeat.comBMO Capital Remains a Buy on Schrodinger (SDGR)July 11, 2025 | theglobeandmail.comMorgan Stanley Assumes Coverage on Schrödinger (SDGR) StockJuly 10, 2025 | finance.yahoo.comAllspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)July 7, 2025 | marketbeat.comSDGR - Schrodinger Inc Ordinary Shares Financials - MorningstarJuly 5, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERAS, ADPT, SDGR, and JANX Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$10.33 +0.09 (+0.88%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.25 -0.08 (-0.77%) As of 08/1/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Erasca NASDAQ:ERAS$1.39 -0.03 (-1.77%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 08/1/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Janux Therapeutics NASDAQ:JANX$23.56 -0.45 (-1.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.59 +0.03 (+0.13%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Schrodinger NASDAQ:SDGR$19.53 -0.80 (-3.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$19.80 +0.27 (+1.38%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
